Cargando…

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent

BACKGROUND: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Procházka, Vít, Pytlík, Robert, Janíková, Andrea, Belada, David, Šálek, David, Papajík, Tomáš, Campr, Vít, Fürst, Tomáš, Furstova, Jana, Trněný, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109941/
https://www.ncbi.nlm.nih.gov/pubmed/25058337
http://dx.doi.org/10.1371/journal.pone.0102594
_version_ 1782327936226951168
author Procházka, Vít
Pytlík, Robert
Janíková, Andrea
Belada, David
Šálek, David
Papajík, Tomáš
Campr, Vít
Fürst, Tomáš
Furstova, Jana
Trněný, Marek
author_facet Procházka, Vít
Pytlík, Robert
Janíková, Andrea
Belada, David
Šálek, David
Papajík, Tomáš
Campr, Vít
Fürst, Tomáš
Furstova, Jana
Trněný, Marek
author_sort Procházka, Vít
collection PubMed
description BACKGROUND: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. METHODOLOGY/PRINCIPAL FINDINGS: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age ≥60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG ≥1, age ≥70, bulk ≥7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. CONCLUSIONS: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.
format Online
Article
Text
id pubmed-4109941
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41099412014-07-29 A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent Procházka, Vít Pytlík, Robert Janíková, Andrea Belada, David Šálek, David Papajík, Tomáš Campr, Vít Fürst, Tomáš Furstova, Jana Trněný, Marek PLoS One Research Article BACKGROUND: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. METHODOLOGY/PRINCIPAL FINDINGS: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age ≥60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG ≥1, age ≥70, bulk ≥7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. CONCLUSIONS: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants. Public Library of Science 2014-07-24 /pmc/articles/PMC4109941/ /pubmed/25058337 http://dx.doi.org/10.1371/journal.pone.0102594 Text en © 2014 Procházka et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Procházka, Vít
Pytlík, Robert
Janíková, Andrea
Belada, David
Šálek, David
Papajík, Tomáš
Campr, Vít
Fürst, Tomáš
Furstova, Jana
Trněný, Marek
A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title_full A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title_fullStr A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title_full_unstemmed A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title_short A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
title_sort new prognostic score for elderly patients with diffuse large b-cell lymphoma treated with r-chop: the prognostic role of blood monocyte and lymphocyte counts is absent
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109941/
https://www.ncbi.nlm.nih.gov/pubmed/25058337
http://dx.doi.org/10.1371/journal.pone.0102594
work_keys_str_mv AT prochazkavit anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT pytlikrobert anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT janikovaandrea anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT beladadavid anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT salekdavid anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT papajiktomas anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT camprvit anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT fursttomas anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT furstovajana anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT trnenymarek anewprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT prochazkavit newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT pytlikrobert newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT janikovaandrea newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT beladadavid newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT salekdavid newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT papajiktomas newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT camprvit newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT fursttomas newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT furstovajana newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent
AT trnenymarek newprognosticscoreforelderlypatientswithdiffuselargebcelllymphomatreatedwithrchoptheprognosticroleofbloodmonocyteandlymphocytecountsisabsent